1. Home
  2. KPTI vs MRT Comparison

KPTI vs MRT Comparison

Compare KPTI & MRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • MRT
  • Stock Information
  • Founded
  • KPTI 2008
  • MRT 2018
  • Country
  • KPTI United States
  • MRT Turkey
  • Employees
  • KPTI N/A
  • MRT N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • MRT Rental/Leasing Companies
  • Sector
  • KPTI Health Care
  • MRT Consumer Discretionary
  • Exchange
  • KPTI Nasdaq
  • MRT Nasdaq
  • Market Cap
  • KPTI 103.5M
  • MRT 117.0M
  • IPO Year
  • KPTI 2013
  • MRT N/A
  • Fundamental
  • Price
  • KPTI $0.64
  • MRT $2.95
  • Analyst Decision
  • KPTI Strong Buy
  • MRT
  • Analyst Count
  • KPTI 4
  • MRT 0
  • Target Price
  • KPTI $5.00
  • MRT N/A
  • AVG Volume (30 Days)
  • KPTI 1.0M
  • MRT 183.5K
  • Earning Date
  • KPTI 11-05-2024
  • MRT 01-01-0001
  • Dividend Yield
  • KPTI N/A
  • MRT N/A
  • EPS Growth
  • KPTI N/A
  • MRT N/A
  • EPS
  • KPTI N/A
  • MRT N/A
  • Revenue
  • KPTI $148,442,000.00
  • MRT $18,953,502.00
  • Revenue This Year
  • KPTI $6.67
  • MRT N/A
  • Revenue Next Year
  • KPTI $8.58
  • MRT N/A
  • P/E Ratio
  • KPTI N/A
  • MRT N/A
  • Revenue Growth
  • KPTI 1.77
  • MRT N/A
  • 52 Week Low
  • KPTI $0.63
  • MRT $0.53
  • 52 Week High
  • KPTI $1.95
  • MRT $3.55
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 25.28
  • MRT 54.85
  • Support Level
  • KPTI $0.75
  • MRT $2.76
  • Resistance Level
  • KPTI $0.83
  • MRT $3.27
  • Average True Range (ATR)
  • KPTI 0.05
  • MRT 0.27
  • MACD
  • KPTI -0.01
  • MRT -0.05
  • Stochastic Oscillator
  • KPTI 4.21
  • MRT 24.05

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About MRT Marti Technologies Inc.

Marti Technologies Inc is a mobility app, operating a fleet of over 48,000 e-mopeds, e-bikes, and e-scooters, serviced by proprietary software systems and IoT infrastructure.

Share on Social Networks: